Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax.
about
The evolution of poxvirus vaccinesSide-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primatesPhase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals.Intradermal delivery of vaccines: potential benefits and current challenges.Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax(®) using proteome microarrays and development of recombinant protein ELISAsFailure of the smallpox vaccine to develop a skin lesion in vaccinia virus-naïve individuals is related to differences in antibody profiles before vaccination, not after.Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications.Impact of anti-orthopoxvirus neutralizing antibodies induced by a heterologous prime-boost HIV-1 vaccine on insert-specific immune responsesSafety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario.Third-generation smallpox vaccines: challenges in the absence of clinical smallpox.MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults.Prime and Boost Vaccination Elicit a Distinct Innate Myeloid Cell Immune Response.
P2860
Q26995905-025CEFC5-35E0-40DA-8528-E327C2E25F83Q27325586-F705F8CC-7405-407F-8331-E7F57CD2E2B7Q33930815-43729BBC-EB0C-48DC-8622-058B92C7D09AQ34601669-D1195934-7120-47F6-AA36-E4DB0AD16D83Q35571248-0DD6F082-7350-4E31-899B-AA86C86F6041Q35634159-1B983383-4880-435F-B897-875CD009E5A0Q35805278-E98CFEEA-35CA-4930-81BC-B0AE28C46805Q35826728-8E752FAA-FA1C-4D8E-86A4-3EFC7D1EDB7BQ36593175-5143C69E-0CB6-415D-A297-300054B55CF0Q37127399-CCC5723D-D7EA-4F97-ABEB-38FD8A64EB1AQ37791160-B6F1FAC6-904B-40D7-810E-C6B500E8987BQ40497816-0782D5C6-F486-48CF-A8B1-462509FA5FFEQ49958499-E96C186B-4B4B-4E96-B509-D12E8DCFC9D7
P2860
Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Effect of vaccination with mod ...... sequent challenge with Dryvax.
@ast
Effect of vaccination with mod ...... sequent challenge with Dryvax.
@en
Effect of vaccination with modified vaccinia Ankara
@nl
type
label
Effect of vaccination with mod ...... sequent challenge with Dryvax.
@ast
Effect of vaccination with mod ...... sequent challenge with Dryvax.
@en
Effect of vaccination with modified vaccinia Ankara
@nl
prefLabel
Effect of vaccination with mod ...... sequent challenge with Dryvax.
@ast
Effect of vaccination with mod ...... sequent challenge with Dryvax.
@en
Effect of vaccination with modified vaccinia Ankara
@nl
P2093
P2860
P356
P1476
Effect of vaccination with mod ...... bsequent challenge with Dryvax
@en
P2093
Ayush Giri
Colleen Devoy
Haesook T Kim
Jane A Kleinjan
Kristen E Stevenson
Lauren E Grandpre
Lizanne C Noble
Marissa B Wilck
Michael S Seaman
Raphael Dolin
P2860
P304
P356
10.1086/651560
P407
P577
2010-05-01T00:00:00Z